COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K8RK
|
|||
Drug Name |
Alisporivir
|
|||
Synonyms |
DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
|
|||
Drug Type |
Protein/peptide drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1], [2] | Severe acute respiratory syndrome (SARS) | Investigative | [2] |
Other Indication | Hepatitis C virus infection | Phase 3 | [3] | |
Therapeutic Class |
Antiviral Agents
|
|||
Company |
Novartis pharmaceuticals
|
|||
Structure |
Download2D MOL
|
|||
Canonical SMILES |
CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
|
|||
CAS Number |
CAS 254435-95-5
|
|||
PubChem Compound ID |
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN cyclophilin A (CYPA) | Target Info | Inhibitor | [1], [2] |
Alisporivir inhibits a broad range of SARS-CoVs in vitro via inhibiting cyclophilin A that interact with SARS-CoV nsp1 to modulate the calcineurin pathway, which is important in the T cell-mediated adaptive immune response. |
References | Top | |||
---|---|---|---|---|
1 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | |||
2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
3 | ClinicalTrials.gov (NCT01500772) Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.